Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
Introduction and objective Multiple myeloma (MM) is an incurable condition with variable clinical course. The study included a group of patients with especially poor-prognosis, individuals with relapsed/refractory multiple myeloma (RRMM) and specific cytogenetic disorders. Among the currently used t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Rural Health
2021-06-01
|
| Series: | Annals of Agricultural and Environmental Medicine |
| Subjects: | |
| Online Access: | http://www.aaem.pl/Efficacy-of-ixazomib-lenalidomide-dexamethasone-in-high-molecular-risk-relapsed-refractory,137788,0,2.html |
| _version_ | 1811328273741774848 |
|---|---|
| author | Aneta Szudy-Szczyrek Sylwia Chocholska Oliwia Bachanek-Mitura Olga Czabak Radosław Mlak Michał Szczyrek Justyna Muzyka-Kasietczuk Marek Hus |
| author_facet | Aneta Szudy-Szczyrek Sylwia Chocholska Oliwia Bachanek-Mitura Olga Czabak Radosław Mlak Michał Szczyrek Justyna Muzyka-Kasietczuk Marek Hus |
| author_sort | Aneta Szudy-Szczyrek |
| collection | DOAJ |
| description | Introduction and objective
Multiple myeloma (MM) is an incurable condition with variable clinical course. The study included a group of patients with especially poor-prognosis, individuals with relapsed/refractory multiple myeloma (RRMM) and specific cytogenetic disorders. Among the currently used therapies the ixazomib-lenalidomid-dexamethasone (IRd) is considered as a candidate to improve outcomes. The aim of the study was to evaluate the safety and efficacy of IRd regimen in the treatment of patients with RMMM.
Material and methods
Nine patients aged 52–82 years who received ixazomib in the early access programme, were included in the study. All patients met the criteria for recurrent/relapsed MM and had high (t(4:14), t(14:16), del17p or +1q21) risk aberrations. Previous chemotherapy regimens included thalidomide and bortezomib. Median duration of exposure to ixazomib was 12 months.
Results
One patient with multiple cytogenetic aberrations and extramedullary plasmocytoma died because of progression after two months of treatment. In the remaining patients, the objective response to treatment was reached, and in four cases it was qualified as a very good partial response (VGPR). Observed adverse effects included neutropenia, infections, and oedema (in three cases Grade 3). Eight patients continue treatment, in two cases the decision was made to reduce lenalidomide doses.
Conclusions
Preliminary results suggest potentially high efficacy and good safety profile of IRd therapy in patients with RRMM and unfavourable cytogenetics. |
| first_indexed | 2024-04-13T15:23:24Z |
| format | Article |
| id | doaj.art-7a8307a3e68d4f7999f18813e8ff6869 |
| institution | Directory Open Access Journal |
| issn | 1232-1966 1898-2263 |
| language | English |
| last_indexed | 2024-04-13T15:23:24Z |
| publishDate | 2021-06-01 |
| publisher | Institute of Rural Health |
| record_format | Article |
| series | Annals of Agricultural and Environmental Medicine |
| spelling | doaj.art-7a8307a3e68d4f7999f18813e8ff68692022-12-22T02:41:35ZengInstitute of Rural HealthAnnals of Agricultural and Environmental Medicine1232-19661898-22632021-06-0129110310910.26444/aaem/137788137788Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature reviewAneta Szudy-Szczyrek0https://orcid.org/0000-0003-2352-394XSylwia Chocholska1https://orcid.org/0000-0002-5001-9258Oliwia Bachanek-Mitura2https://orcid.org/0000-0002-5409-8133Olga Czabak3https://orcid.org/0000-0002-9083-9058Radosław Mlak4https://orcid.org/0000-0001-7399-8340Michał Szczyrek5https://orcid.org/0000-0002-1271-2254Justyna Muzyka-Kasietczuk6https://orcid.org/0000-0002-6569-8396Marek Hus7https://orcid.org/0000-0002-9036-6625Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandDepartment of Human Physiology, Medical University of Lublin, PolandChair and Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, PolandIntroduction and objective Multiple myeloma (MM) is an incurable condition with variable clinical course. The study included a group of patients with especially poor-prognosis, individuals with relapsed/refractory multiple myeloma (RRMM) and specific cytogenetic disorders. Among the currently used therapies the ixazomib-lenalidomid-dexamethasone (IRd) is considered as a candidate to improve outcomes. The aim of the study was to evaluate the safety and efficacy of IRd regimen in the treatment of patients with RMMM. Material and methods Nine patients aged 52–82 years who received ixazomib in the early access programme, were included in the study. All patients met the criteria for recurrent/relapsed MM and had high (t(4:14), t(14:16), del17p or +1q21) risk aberrations. Previous chemotherapy regimens included thalidomide and bortezomib. Median duration of exposure to ixazomib was 12 months. Results One patient with multiple cytogenetic aberrations and extramedullary plasmocytoma died because of progression after two months of treatment. In the remaining patients, the objective response to treatment was reached, and in four cases it was qualified as a very good partial response (VGPR). Observed adverse effects included neutropenia, infections, and oedema (in three cases Grade 3). Eight patients continue treatment, in two cases the decision was made to reduce lenalidomide doses. Conclusions Preliminary results suggest potentially high efficacy and good safety profile of IRd therapy in patients with RRMM and unfavourable cytogenetics.http://www.aaem.pl/Efficacy-of-ixazomib-lenalidomide-dexamethasone-in-high-molecular-risk-relapsed-refractory,137788,0,2.htmllenalidomidehigh riskixazomibcytogeneticrelapsed/refractory multiple myeloma |
| spellingShingle | Aneta Szudy-Szczyrek Sylwia Chocholska Oliwia Bachanek-Mitura Olga Czabak Radosław Mlak Michał Szczyrek Justyna Muzyka-Kasietczuk Marek Hus Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review Annals of Agricultural and Environmental Medicine lenalidomide high risk ixazomib cytogenetic relapsed/refractory multiple myeloma |
| title | Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review |
| title_full | Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review |
| title_fullStr | Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review |
| title_full_unstemmed | Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review |
| title_short | Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review |
| title_sort | efficacy of ixazomib lenalidomide dexamethasone in high molecular risk relapsed refractory multiple myeloma case series and literature review |
| topic | lenalidomide high risk ixazomib cytogenetic relapsed/refractory multiple myeloma |
| url | http://www.aaem.pl/Efficacy-of-ixazomib-lenalidomide-dexamethasone-in-high-molecular-risk-relapsed-refractory,137788,0,2.html |
| work_keys_str_mv | AT anetaszudyszczyrek efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT sylwiachocholska efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT oliwiabachanekmitura efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT olgaczabak efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT radosławmlak efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT michałszczyrek efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT justynamuzykakasietczuk efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview AT marekhus efficacyofixazomiblenalidomidedexamethasoneinhighmolecularriskrelapsedrefractorymultiplemyelomacaseseriesandliteraturereview |